NCT04486482

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Kaleido Biosciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.

Conditions

• Mild-to-Moderate COVID-19

Interventions

Type	Name	Description
OTHER	KB109 + Self Supportive Care (SSC)	KB109 is a novel glycan
OTHER	Self Supportive Care (SSC) Alone	Self Supportive Care (SSC) Alone

Timeline

• Start date: 2021-01-12
• Primary completion: 2021-03-30
• Completion: 2021-03-30
• First posted: 2020-07-24
• Last updated: 2021-08-13

Locations

12 sites across 1 country: United States